Poster References

This list of included articles is based on preliminary data-extraction for the CAG 2022 Conference.

Adhiyaman, V., & Arshad, S. (2014). Cannabis for intractable nausea after bilateral cerebellar stroke. Journal of the American Geriatrics Society62(6), 1199.

Ahmed, A. I., van den Elsen, G. A., Colbers, A., Kramers, C., Burger, D. M., van der Marck, M. A., & Olde Rikkert, M. G. (2015). Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology232(14), 2587–2595.

Cohen, L. M., Ash, E., Outen, J. D., Vandrey, R., Amjad, H., Agronin, M., Burhanullah, M. H., Walsh, P., Wilkins, J. M., Leoutsakos, J. M., Nowrangi, M. A., Harper, D., Rosenberg, P. B., & Forester, B. P. (2021). Study rationale and baseline data for pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer’s dementia (THC-AD). International psychogeriatrics, 1–6. Advance online publication.

Chagas, M. H., Eckeli, A. L., Zuardi, A. W., Pena-Pereira, M. A., Sobreira-Neto, M. A., Sobreira, E. T., Camilo, M. R., Bergamaschi, M. M., Schenck, C. H., Hallak, J. E., Tumas, V., & Crippa, J. A. (2014). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. Journal of clinical pharmacy and therapeutics39(5), 564–566.

Holden, S. K., Domen, C. H., Sillau, S., Liu, Y., & Leehey, M. A. (2022). Higher Risk, Higher Reward? Self-Reported Effects of Real-World Cannabis Use in Parkinson’s Disease. Movement disorders clinical practice9(3), 340–350.

Passmore M. J. (2008). The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. International journal of geriatric psychiatry23(1), 116–117.

Ruthirakuhan, M., Herrmann, N., Andreazza, A.C., Verhoeff, N.P.L., Gallagher, D., Black, S.E. and Lanctot, K.L. (2020), Biomarkers of agitation in moderate-to-severe Alzheimer’s disease patients enrolled in an RCT with nabilone. Alzheimer’s Dement., 16: e042269.

Tumati, S., Lanctôt, K.L., Wang, R. et al. Medical Cannabis Use Among Older Adults in Canada: Self-Reported Data on Types and Amount Used, and Perceived Effects. Drugs Aging 39, 153–163 (2022).

van den Elsen, G., Ahmed, A., Verkes, R. J., Feuth, T., van der Marck, M. A., & Olde Rikkert, M. (2015). Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry23(12), 1214–1224.

Volicer, L., Stelly, M., Morris, J., McLaughlin, J., & Volicer, B. J. (1997). Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. International journal of geriatric psychiatry12(9), 913–919.

Walther, S., Mahlberg, R., Eichmann, U., & Kunz, D. (2006). Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology185(4), 524–528.

Back to Poster